Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
probably the easier path of recourse is against CNBC and Meg Tirrell.
JT could demand another interview and a retraction (mea culpa would more satisfying but unlikely) from them.
Yep routine and yep someone should but..
definitely b;
Great post concapk.
yep i was relieved how it closed. i scrambled all day trying to increase my share count and was moderately successful.
oh the razor was for shaving and the soma for relaxing (ref. 1984)
oops wrong old novel duh "Brave New World" damn getting old is confusing LOL.
Seeking Alpha news editor Douglas House reports:
Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study
Nov. 11, 2018 4:18 PM ET|About: Amarin Corporation PLC (AMRN)|By: Douglas W. House, SA News Editor
Results from the 8,179-subject REDUCE-IT study evaluating Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in statin-treated adults with elevated cardiovascular (CV) risk showed a significant treatment effect.
The data were presented at the AHA Scientific Sessions in Chicago and simultaneously published in the New England Journal of Medicine.
REDUCE-IT assessed 4 g/day of Vascepa over a median of 4.9 years. It achieved the primary endpoint of a statistically valid 25% (hazard ratio = 0.75) reduction in a composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary revascularization and unstable angina requiring hospitalization compared to statin therapy alone.
Patients receiving Vascepa on top of statin therapy experienced 31% less risk of a heart attack, 35% less risk of urgent/emergent revascularization (stent or bypass surgery), 20% less risk of CV death, 32% less risk of hospitalization for unstable angina and 28% less risk of stroke. The risk of total mortality (CV and non-CV) was reduced 13%.
The CV benefits did not appear to significantly influenced by triglyceride levels between 135 mg/dL and 499 mg/dL at baseline, the targeted patient population for the company's planned supplemental marketing application on tap for early 2019 [Vascepa is currently approved in the U.S. for patients with severe hypertriglyceridemia (at least 500 mg/dL)].
The company emphasizes the low cost of Vascepa compared to alternatives, with a monthly copay of $9.99 or less and the cost of a 90-day supply for as little as $9, depending on the type of insurance coverage.
Management says it is in the process of expanding its U.S. salesforce to over 400 headcount.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
https://seekingalpha.com/news/3408347-amarins-vascepa-reduced-major-adverse-cardiovascular-events-25-percent-large-scale-reduce
Hey Nuke I got your post Plus Oned so now we have a quick reference to the link.
This morning's "The Readout" from Stat;
"Amarin’s moment of truth
Shares of the biotech company Amarin are up almost tenfold since September, when the company said that its modest-selling cardiovascular drug led to major long-term improvements in patient health.
But that was based on a few figures in a press release. This weekend, we’ll find out all the gritty details, which will determine whether Amarin’s pill is really a major advance in cardiovascular care or whether there’s a sizable asterisk lurking somewhere in the data.
On Saturday, the company will present the full results of its study at the American Heart Association’s annual gathering in Chicago. If the results hold up, one of the year’s most surprising stories in biotech will only get better. If not, Amarin’s $6.6 billion market cap might not make it through Monday.
Stay tuned to STAT for the news once it happens."
https://www.statnews.com/category/the-regulars/the-readout/?utm_source=STAT+Newsletters&utm_campaign=6d68b132eb-MR_COPY_03&utm_medium=email&utm_term=0_8cab1d7961-6d68b132eb-150805797
HaHaHa Shirley you jest.
announced topline 3/14/2016. data on the trial results were presented at ASCO which is always either end of May or beginning of June. that year ASCO was end of May so they were bought when they presented data from trial at ASCO.
I used to be purple but becoming more blue with every tweet. sad
CC, click on his volcano avatar and his posts will magically appear.
jl i hope you write an autobiography. it could be a best seller... well i certainly would buy it.
yes misinterpreted:
check your IHUB mailbox :)
Hey mav, really nice to read your posts again..i had missed deciphering your connotations. :)
i have been taking OV 500 for more than 1.5 years and have definitely realized some benefits such as way fewer aches and pains and better mood as well as lower cholesterol.
i do take a very low dose simvastatin and did a personal wash out trial of stopping the statin for 3 months before my blood work and my cholesterol levels did increase significantly but not to the levels before the statin and OV 500.
i see my Doc again in late Nov and am going to plead with him to give me a RX for Vascepa. BTW i did tell him about AMRN quite a while ago and he told me about EXAS. I didn't bite and neither did he. so far he is ahead but i'm gaining quickly. :)
excellent post stockboy. 2 thumbs up
Chill Afford (his previous handle). you can stop posting your insecurities please. you done good by leaving NWBO and landing here.
just chillax and don't watch the ticker, AMRN is as good a stock as you can find.
You know me from over there and you know i don't BS.
marzan can you sticky jl's post? TY
BB = Best Squeaky Wheel ever!!
Nice BioChica. with all the new wealth received by posters on this board we could fund our own algae farm...
how do i get ahold of you again? i'll be at the Marriot Grand Chateau 1-11-19 thru 1-18-19 so i'll probably need to book 3 more nights at the Venetian with y'all.
Hey Kev, There is a Topgolf a couple of blocks across Las Vegas Blvd. from Aria. It has a Signature room with hitting bays alongside that can accommodate up to 250. Could be real fun for Friday or Saturday.
Hi Investor, not all of us are risk adverse. see my recent posts. i still have a little AVXL. But i plan on coming back with a lot more juice in Jan. Believe me there is still tremendous upside.
good luck to all here. i miss some of you but it is too contentious here to read this board very often.
FF thanks for this..
YES you can transfer but make sure you note your cost basis. i transfer shares last week and the agent promised promised me that "oh we do that now". i had asked him specifically about that situation and of course cost basis not transferred. took every bit of 3 days too. my bad for believing him. :(
if you buy after the sale on the same day they settle the same day so the purchase is deemed settled the same time the sale is settled and so is allowed.
sorry i've been doing it in my IRA for years. you just have to be aware you cant sell within 3 days. i've had my hand (Acct) slapped a few times, the worst was a restriction that i couldn't do it again(trade same stock same day) for 30 days.
Nope in my IRA i sold 10 contracts of Oct 19 $2 today and bought 30 Jan 18 $20 and 30 Mar 15 $24 call today. i cannot( should not) sell either one for 2days. It's 2days for options and 3 days for stocks.
i misread your question
yep you are right. lots of ways to play it. i would sell some to exercise the rest. tax rates can change so you never know.
Thanks Tasty. I've never held options that long so i didn't know that.
With $4 strike its a no brainer for you to sell them instead of exercise then right?
cool i think i have a Grazie card. i really want to go but i want to go to SF as well.. a 2+ week west coast trip would be easy solo but i'd rather not.. hmm
It's not 'fish oil' it's icosapent ethyl a FDA approved drug.
repeat after me
icosapent ethyl a FDA approved drug. :)
Dang.. This light volume is killing us
'Man, Oh Manischewitz' what a stock er.. wine.
I think he can expound on what he has already stated and PRed. He can also differentiate the differences between fish oil and Vascepa.
Amarin to Present at the Cantor Global Healthcare Conference
NEW 5 COIN FAUCET
https://ih.advfn.com/faucet/cdpuwh PURA 5 coin
Updated but same links as before
https://ih.advfn.com/faucet/p91evp AUXLY 5 COINS
https://ih.advfn.com/faucet/br4vgp TIDAL 5 COINS
https://ih.advfn.com/faucet/zoe5ul alyi 5 coin
uk wall:
https://uk.advfn.com/faucet/nmt8vr trading systems UK 1COIN